{"id":"jpi-289-high-dose","_chembl":{"chemblId":"CHEMBL5314421","moleculeType":"Small molecule","molecularWeight":"452.38"},"_dailymed":null,"_scrapedAt":"2026-03-28T01:57:35.961Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123952,"model":"claude-sonnet-4-5-20250929"},"description":"JPI-289 High-dose is an investigational therapeutic agent being developed by Jeil Pharmaceutical Co., Ltd. currently in Phase 2 clinical trials. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this time.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT03062397","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-12-09","conditions":"Acute Ischemic Stroke","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"JPI-289 High-dose","genericName":"JPI-289 High-dose","companyName":"Jeil Pharmaceutical Co., Ltd.","companyId":"jeil-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}